Gala vs MEDVi: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
MEDVi beats Gala overall, scoring 7.7/10 vs 7/10. Gala is more affordable at $149/mo vs $299/mo. Choose Gala for users who want low-cost compounded tirzepatide and a built-i. Choose MEDVi for users who want a low entry price with oral and injectable co.
A side-by-side comparison of Gala and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.
Gala
#40 of 42Telehealth platform offering compounded semaglutide and tirzepatide at competitive pricing, plus a paid path to brand semaglutide. Differentiator: a dedicated iOS GLP-1 tracker app for users who want to log dosing, weight, and side effects in one place.
Visit GalaMEDVi
#20 of 42MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake — one of the broader compounded mixes among independent telehealth providers in 2026.
Visit MEDVi| Feature | Gala | MEDVi |
|---|---|---|
| Our Score | 7/10 | 7.7/10 |
| Starting Price | $149/mo | $299/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Users who want low-cost compounded tirzepatide and a built-in iOS tracker app for daily progress logging | Users who want a low entry price with oral and injectable compounded options |
| Ranking | #40 | #20 |
Pros & Cons Compared
Gala
Pros
- +Compounded tirzepatide as low as $149/mo on the longest commitment plan — among the cheapest tirz options on the market
- +$199/mo entry pricing on a 3-month plan for compounded semaglutide — competitive in the mid-tier
- +Dedicated 'Gala GLP-1 Tracker' iOS app for dosing, weight, and side-effect logging — uncommon among compounded-only platforms
- +Both semaglutide and tirzepatide available, plus a brand-name semaglutide path for users who specifically want FDA-approved
Cons
- −Brand-name semaglutide pricing ($1,299/mo) is significantly above market — NovoCare direct pricing for Wegovy is $349/mo
- −Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness
- −Newer brand (Delaware-registered, limited public company history) — less track record than established platforms like Henry Meds or Sprout
- −No published lab panels or specialty clinical oversight — state-licensed prescriber review is the standard, not differentiated
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
MEDVi edges out Gala with a score of 7.7/10 vs 7/10. If budget is your priority, Gala starts at $149/mo compared to MEDVi's $299/mo. Choose Gala if you want: users who want low-cost compounded tirzepatide and a built-in ios tracker app for daily progress logging. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.